Summary. This report studies prolactin secretion in infertile men and the effect of bromocriptine treatment.
1971). Specific radioimmunological determination enabled us to undertake the physiopathological study of prolactin secretion.
It rapidly became evident that, due to a plasmatic half-life of about 15 min, a circadian rhythm (Nokin et al., 1972) and the effect of stress (sometimes considerable) (Noel et al., 1972) , the interpretation of an isolated prolactinemia value was hazardous. It was thus necessary to carry out dynamic tests to estimate the stimulation or inhibition of secretion ; these tests used either TRH (thyrotropin-releasing hormone), known to release prolactin (Bowers et al., 1973 ; Jacobs et al., 1971) , or rye ergot derivatives such as bromocriptine which inhibits prolactin secretion (Besser et al., 1972 ; Del Pozo et al., 1972) .
The relationships between prolactin secretion and the male gonadic function are not yet well known, especially in man ; however, some studies suggest that prolactin has a stimulatory effect. According to these, prolactin would increase the testosterone secretion (Rubin et al., 1975) , and an induced hyperprolactinemia would be accompanied by testosterone response, greater after stimulation by HCG (Ambrosi et al., 1976) .
On the other hand, contrasting results favor an inhibitory effect. The majority of hyperprolactinemic patients are hypogonadic or impotent (Boyar et al., 1974 ; Thorner et at., 1974 ; Fossati, Strauch and Tourniaire, 1976) ; induced hyperprolactinemia is followed by lower DHT response after stimulation by HCG (Magrini et al., 1976) and induced hypoprolactinemia is accompanied by increased testosterone secretion after HCG (Besser and Thorner, 1975) .
Given these apparently contradictory results, the aim of this report is to study prolactin secretion in normal and infertile men, and to determine the consequences of curbing prolactin secretion with bromocriptine.
Material and methods. Spermogram study. In the whole group (18 subjects) the treatment caused large changes in the number of spermatozoa per ml ; this significantly increased from 15.5 ! 2.8 x 10 6 before treatment (extreme values 0.35 to 45.0 X 10 6 ) to 31.6 ! 6.1 X 10 6 after treatment (extreme values 0.35 to 105.0 X 10 6 ). On the other hand, motility one hour after emission, the number of normal forms and the volume of ejaculation were not statistically modified. Thus, 11 subjects showed definite improvement, 3 remained unchanged, 2 presented more spermatozoa per ml but a considerable decrease in motility, and 2 showed a decrease in the number and the motility of spermatozoa.
In the 9 subjects who presented basal prolactinemia higher than 300 !U/m! before treatment, we noted a significant increase in the number of spermatozoa per ml, i.e. 17.0 ! 3.3 X 10 6 before treatment to 44.7 ±10.3 X 10 6 after treatment (extreme value were from 0.4 to 36.0 X 10 6 /ml and from 1.4 to 105.0 X 10 6 / M l, respectively). Eight subjects showed definite improvement, the increase being higher than 60 p. 100 for each individual. In one case, the number of spermatozoa was only slightly modified.
In the 9 subjects who presented basal prolactinemia lower than 300 !tU/ml before treatment and increased prolactineamia higher than 800 >U/ml after TRH (OP), we noted in 3 cases a definite increase in the number of spermatozoa, in 2 cases no change, in 2 cases more spermatozoa per ml but a noticeable decrease in motility, and in 2 cases a considerable decrease in both number and motility. A statistical study of the spermograms of the whole group did not reveal any significant variations.
Discussion.
The functioning and degree of malfunction of the hypothalamopituitary-gonadic axis in infertile men can be defined using the LH-RH test (Franchimont et al., 1973 ; Boucher et al.,1976 (Setchell, 1974 ; Franchimont et al., 1975) .
Prolactin and gonadotropins.
The prolactin level we observed before or after TRH in a normal healthy man corresponds to that noted by other authors (L'Hermite et al., 1975 ; Franchimont et al., 1976 (Johansson, 1975 (Johansson, , 1976 .
Prolactin associate with LH in vivo restores normal testosteronemia in hypophysectomized rat (Hafiez, Llyod and Bartke, 1972) , and intervenes in testis and accessory organ development (Negro-Vilar, Krulich and MacCann, 1973) . In the male hamster exposed to short day length, prolactin significantly increases the weight of testis, seminal vesicles and prostate gland, as well as increasing plasma testosterone level (Bartke, Croft and Dalterio, 1975) . Testosterone peaks in man are preceded by peaks of LH and prolactin 60 min beforehand (Rubin, Poland and Tower, 1976) , and an increase in prolactin is followed by an increase in testosterone (Rubin et al., 1975 (Delvoye et a/., 1974) . TRH treatment producing hyperprolactinemia is followed by suppression of the preovulatory LH surge (Bohnet, Dahlen and Schneider, 1974) . Hyperprolactinemia in women is very often accompanied by amenorrhea, and in men by impotence or hypogonadism (Thorner et al., 1974 ; Fossati, Strauch and Tourniaire, 1976) ; androgen secretion consecutive to HCG treatment is greater when prolactin is inhibited (Besser and Thorner, 1975) .
In rat, experimental hyperprolactinemia, consecutive to transplant of a prolactin pituitary tumor, is followed by a lower testosterone level, genital atrophy and spermiogenetic arrest (Fang, Refetoff and Rosenfield, 1974 Most of the studies using bromocriptine have been carried out on women, in particular during the amenorrhea-galactorrhea syndrome. This rye ergot alkaloid inhibits the secretion of prolactin (Del Pozo et al., 1972) , and its use in cases of hyperprolactinemia provokes the reappearance of the menstrual cycle in most cases (Besser et al., 1972 ; Del Pozo et al., 1974 ; Seki, Seki and Okumura, 1975 ; Fossati, Strauch and Tourniaire, 1976 ). Bromocriptine does not modify LH or FSH, but increases estradiol secretion (Seppala et al., 1976 
